Abstract
Local injection of autologous bone marrow-derived aldehyde dehydrogenase bright (ALDHbr) cells (in the dosage and manner described) into the thigh and calf of patients with claudication does not improve peak walking disease (PWT) or magnetic resonance imaging (MRI) capillary perfusion nor were there demonstrated quality of life (QOL) improvements. In patients with completely occluded superficial femoral arteries, the number of collateral arteries did increase with ALDHbr cell injection on post hoc analysis, which suggests a potential benefit in those with more advanced disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
